DGAP-News: Neovacs SA

DGAP-News: Neovacs to Present at Bio International Convention 2016

DGAP-News: Neovacs S.A. / Key word(s): Conference Neovacs to Present at Bio International Convention 2016

30.05.2016 / 08:00 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Neovacs to Present at Bio International Convention 2016

Paris and Boston, May 30th, 2016 - Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the Bio International Convention, one of the major international conventions focused on the biotechnology industry, being held June 6 to 9, 2016, in San Francisco, CA.

The Convention brings together established and emerging leaders in the global biotechnology and pharmaceutical industry. In a presentation on Monday, June 6, at 2:30pm PDT (UTC-7 pm), Miguel Sieler, CEO of Neovacs will discuss the Company's proprietary Kinoid technology, providing updates about Neovacs' pipeline and strategic development programs for 2016/2017. He will also be accompanied by two members of the scientific management team: Dr Thérèse Croughs, Chief Medical officer, and Geraldine Vogel, Scientific Director of Neovacs.

"We are pleased to participate in this event, which is an excellent opportunity to meet other major companies from our industry," commented Miguel Sieler, CEO of Neovacs. "This year, our participation will be more significant, as we obtained IND approval from the Food and Drug Administration in the United States for our Phase IIb study of IFNa-Kinoid in the treatment of Lupus, which allows us to broaden our visibility and increase the interest in our technology platform."

Meet Neovacs' team at booth #413, South & North Hall

of the Moscone Center in San Francisco, California, USA

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts NEOVACS - Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 cmasson@neovacs.com

Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-21-02-28-30 raimund.gabriel@mc-services.eu

Press / U.S. Inquiries - The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 lroth@theruthgroup.com / jgreen@theruthgroup.com

---------------------------------------------------------------------------

30.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News Service ---------------------------------------------------------------------------

467283 30.05.2016